Last reviewed · How we verify
GSK2269557 750 µg
GSK2269557 750 µg is a Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 1 development.
At a glance
| Generic name | GSK2269557 750 µg |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) (PHASE2)
- Safety, Tolerability and Pharmacokinetics (PK) Study of GSK2269557 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK2269557 750 µg CI brief — competitive landscape report
- GSK2269557 750 µg updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about GSK2269557 750 µg
What is GSK2269557 750 µg?
GSK2269557 750 µg is a Small molecule drug developed by GlaxoSmithKline.
Who makes GSK2269557 750 µg?
GSK2269557 750 µg is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).
What development phase is GSK2269557 750 µg in?
GSK2269557 750 µg is in Phase 1.
Related
- Manufacturer: GlaxoSmithKline — full pipeline
- Compare: GSK2269557 750 µg vs similar drugs
- Pricing: GSK2269557 750 µg cost, discount & access